Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis
Open accessAbstract
Background . The prevalence of primary biliary cholangitis (PBC), which is an autoimmune liver disease, has increased over time. PBC often leads to severe consequences, such as liver failure and death. Stratification tools using biochemical liver tests are needed to assess and predict the progression of this disease at the time of PBC diagnosis. Methods . We searched PubMed, Cochrane Library, Web of Science, and Embase for studies focused on the relationship between positive rates of Gp210 antibodies and poor prognosis of PBC. The primary end point was the number of PBC patients with poor outcome in the Gp210 antibody (+) and Gp210 antibody (−) groups. The secondary end point was the basic serum level of alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin (TBIL), and IgM in the two groups. The age and number of female patients were also measured. Results . A total of 5 studies, comprising 737 patients, were included in this analysis. A positive rate of Gp210 antibodies was positively correlated with poor outcomes and with many types of progression in PBC, especially liver failure. Mortality was also higher in the Gp210 antibody (+) group. Furthermore, the serum levels of ALP and IgM were associated with the positive rate of Gp210 antibodies, while the serum levels of ALT and TBIL were not. The age and number of female patients were also not associated with the positive rate of Gp210 antibodies. Conclusion . PBC-specific Gp120 antibodies are optimal predictors of PBC prognosis at the time of diagnosis. Some other liver function indicators, such as ALP and IgM, can be used as predictors to complement Gp210 antibodies to establish a stratification tool to predict the prognosis of PBC at the time of diagnosis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Anti-gp210 and anti-sp100 are also prognostic risk factors for worse disease outcomes in primary biliary cholangitis.
“Anti-gp210 and anti-sp100 are also prognostic risk factors for worse disease outcomes.52,54”
From Primary biliary cholangitis. (2024) · cites this paper as [54]
Section 3.3 reports a higher incidence of poor prognosis in anti-gp210-positive PBC patients (RR 3.08, 95% CI 2.23–4.25). The paper does not report whether anti-sp100 predicts worse outcomes, so it supports only the anti-gp210 part of the sentence. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480 · cited 1× · see citing works
“However, large samples and multicenter studies are needed to confirm the correlation between Gp210 antibody (+) rate and prognosis of PBC [8].”
BackgroundLindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913 · cited 1× · see citing works
“Inclusion criteria were as follows [12, 13]: (1) chronic cholestasis after exclusion of other causes of liver disease, (2) unexplained elevation of serum ALP, (3) positivity of AMA, and (4) liver biopsy which was used to substantiate the diagnosis, but was rarely needed.”
BackgroundPrognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816 · cited 1× · see citing works
“as important predictors of survival in PBC after UDCA treatment [26, 27].”
BackgroundParés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756 · see citing works
Carey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735 · see citing works
Lammers, W. J., Hirschfield, G. M., Corpechot, C., Nevens, F., Lindor, K. D., Janssen, H. L. A., Floreani, A., Ponsioen, C. Y., Mayo, M. J., Invernizzi, P., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.061 · Cited by 441 · see citing works
Management of primary biliary cirrhosis
Heathcote, J. (2000) · Hepatology · doi:10.1053/he.2000.5984 · Cited by 412 · see citing works
Nakamura, M., Kondo, H., Mori, T., Komori, A., Matsuyama, M., Ito, M., Takii, Y., Koyabu, M., Yokoyama, T., Migita, K., et al. (2007) · Hepatology · doi:10.1002/hep.21472 · Cited by 365 · see citing works
Carbone, M., Sharp, S. J., Flack, S., Paximadas, D., Spiess, K., Adgey, C., Griffiths, L., Lim, R., Trembling, P., Williamson, K., et al. (2016) · Hepatology · doi:10.1002/hep.28017 · Cited by 354 · see citing works
ter Borg, P. C. J., Schalm, S. W., Hansen, B. E., & van Buuren, H. R. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00699.x · Cited by 160 · see citing works
Liu, H., Norman, G. L., Shums, Z., Worman, H. J., Krawitt, E. L., Bizzaro, N., Vergani, D., Bogdanos, D. P., Dalekos, G. N., Milkiewicz, P., et al. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2010.09.005 · Cited by 130 · see citing works
Umemura, T., Joshita, S., Sekiguchi, T., Usami, Y., Shibata, S., Kimura, T., Komatsu, M., Matsumoto, A., Ota, M., & Tanaka, E. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.118 · Cited by 127 · see citing works
Nakamura, M., Shimizu‐Yoshida, Y., Takii, Y., Komori, A., Yokoyama, T., Ueki, T., Daikoku, M., Yano, K., Matsumoto, T., Migita, K., et al. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.11.016 · Cited by 126 · see citing works
ITOH, S., Ichida, T., Yoshida, T., Hayakawa, A., UCHIDA, M., Tashiro‐Itoh, T., Matsuda, Y., Ishihara, K., & Asakura, H. (1998) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1998.01553.x · Cited by 117 · see citing works
Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis
Shimoda, S., Nakamura, M., Ishibashi, H., Kawano, A., Kamihira, T., Sakamoto, N., Matsushita, S., Tanaka, A., Worman, H. J., Gershwin, M. E., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00387-1 · Cited by 113 · see citing works
Yang, F., Yang, Y., Wang, Q., Wang, Z., Miao, Q., Xiao, X., Wei, Y., Bian, Z., Sheng, L., Chen, X., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13927 · Cited by 88 · see citing works
Christensen, E., Altman, D., Neuberger, J., Stavola, B. D. D., Tygstrup, N., & Williams, R. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)91086-w · Cited by 87 · see citing works
Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis
Reshetnyak, V. I. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i25.7683 · Cited by 85 · see citing works
Apoptosis, tolerance, and regulatory T cells – old wine, new wineskins
Ferguson, T. A., Stuart, P. M., Herndon, J., & Griffith, T. S. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00042.x · Cited by 72 · see citing works
Clinical Significance of Autoantibodies in Primary Biliary Cirrhosis
Nakamura, M. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1383732 · Cited by 69 · see citing works
Nakamura, M., Takii, Y., Ito, M., Komori, A., Yokoyama, T., Shimizu‐Yoshida, Y., Koyabu, M., Matsuyama, M. M., Mori, T., Kamihira, T., et al. (2005) · Journal of Autoimmunity · doi:10.1016/j.jaut.2005.10.007 · Cited by 50 · see citing works
Haruta, I., Kikuchi, K., Hashimoto, E., Nakamura, M., Miyakawa, H., Hirota, K., Shibata, N., Kato, H., Arimura, Y., Kato, Y., et al. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.40 · Cited by 41 · see citing works
Meta-Analysis Assessment of GP210 and SP100 for the Diagnosis of Primary Biliary Cirrhosis
Hu, S., Zhao, F.-R., Hu, Q., & Chen, W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101916 · Cited by 40 · see citing works
Haruta, I., Kikuchi, K., Hashimoto, E., Kato, H., Hirota, K., Kobayashi, M., Miyake, Y., Uchiyama, T., Yagi, J., & Shiratori, K. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.01.010 · Cited by 13 · see citing works
Haruta, I., Kikuchi, K., Nakamura, M., Hirota, K., Kato, H., Miyakawa, H., Shibata, N., Miyake, Y., Hashimoto, E., Shiratori, K., et al. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9712-1 · Cited by 7 · see citing works
Yao, J., Han, W., Ren, X., Yuan, L., Xu, J., & Duan, Z. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s201564 · Cited by 6 · see citing works
Self-citationTakeshita, Y., Takamura, T., Inoue, O., Okumura, M., Kato, K., Sunagozaka, H., Arai, K., Misu, H., Nakamura, M., Nakanuma, Y., et al. (2012) · Internal Medicine · doi:10.2169/internalmedicine.51.6477 · Cited by 5 · see citing works
Yang, J., Yang, J.-H., You, L.-Y., Xu, Z., & Yang, L. (2009) · PubMed · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tanaka, A., Ma, X., Takahashi, A., & Vierling, J. M. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01303-5 · Cited by 177 · see citing works
You, H., Ma, X., Efe, C., Wang, G., Jeong, S.-H., Abe, K., Duan, W., Chen, S., Kong, Y., Zhang, D., et al. (2022) · Hepatology International · doi:10.1007/s12072-021-10276-6 · Cited by 133 · see citing works
Review article: pathophysiology and management of primary biliary cholangitis
Leung, K. K., Deeb, M., & Hirschfield, G. M. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16023 · Cited by 39 · see citing works
Role of autoantibodies in the clinical management of primary biliary cholangitis
Rigopoulou, E. I., & Bogdanos, D. P. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i12.1795 · Cited by 30 · see citing works
Changes of Serum IgG Glycosylation Patterns in Primary Biliary Cholangitis Patients
Zeng, X., Li, S., Tang, S., Li, X., Zhang, G., Li, M., Zeng, X., & Hu, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669137 · Cited by 24 · see citing works
Bauer, A., Habior, A., Wieszczy, P., & Gaweł, D. (2021) · Diagnostics · doi:10.3390/diagnostics11040587 · Cited by 15 · see citing works
Bauer, A., Habior, A., & Gaweł, D. (2022) · Biomedicines · doi:10.3390/biomedicines10040801 · Cited by 15 · see citing works
Autoantibodies in Primary Biliary Cholangitis
Leung, K. K., & Hirschfield, G. M. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.004 · Cited by 15 · see citing works
Role of Antinuclear Antibodies in Primary Biliary Cholangitis
Levy, C., & Bowlus, C. L. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000765 · Cited by 14 · see citing works
Wang, Z., Li, Y., Ren, L., Li, Y., Xu, T., Li, W., Gao, W., Sun, G., & Liu, M. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1161 · Cited by 10 · see citing works
Liu, H.-L., Liu, X., Hu, Y., Chen, M., Li, S. S., Wang, X., Bao, Y. J., Zhang, Y., Wang, L., Li, R., et al. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70614 · Cited by 9 · see citing works
Risk Stratification in Primary Biliary Cholangitis
Martini, F., Balducci, D., Mancinelli, M., Buzzanca, V., Fracchia, E., Tarantino, G., Benedetti, A., Marzioni, M., & Maroni, L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175713 · Cited by 9 · see citing works
The evolving potential of precision medicine in the management of autoimmune liver disease
Norman, G. L., Bizzaro, N., Villalta, D., Vergani, D., Mieli‐Vergani, G., Hirschfield, G. M., & Mähler, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820239-5.00012-7 · Cited by 5 · see citing works
Caines, A. N., Lü, M., Wu, T., Trudeau, S., Melkonian, C., González, H. C., Sahota, A. K., Schmidt, M. A., Daida, Y. G., Bowlus, C. L., et al. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.17035 · Cited by 3 · see citing works
Autoantibodies in Primary Biliary Cholangitis: From Classical Markers to Emerging Targets
Mimura, S., Morishita, A., Oura, K., Yano, R., Nakahara, M., Tadokoro, T., Fujita, K., Tani, J., Tatsuta, M., Himoto, T., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238503 · Cited by 4 · see citing works
Dias, B., Aguiar, A., Morais, C. I., & Nery, F. (2023) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002565 · Cited by 3 · see citing works
Autoantibodies in the diagnostics, prognostics and follow-up of primary biliary cholangitis
Antal‐Szalmás, P., Bencze, D., Demeter, S., Pénzes, K., Szabó, L., Tóth, B., Földesi, R., Papp, M., & Nagy, G. (2026) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2026.100366 · Cited by 2 · see citing works
Evaluation of autoimmune liver disease antibodies in hepatitis patients
Kim, N., Kim, S., Choi, J. R., & Park, Y. (2024) · PLoS ONE · doi:10.1371/journal.pone.0307285 · Cited by 2 · see citing works
Autotaxin: A Potential biomarker for primary biliary cholangitis
Yang, Y., Liu, B., Zang, B., Liu, Q., Zhao, C., Yao, Y., & Liu, B. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23438 · Cited by 2 · see citing works
Optimizing Care in Primary Biliary Cholangitis: Current Treatments and the Second-Line Decision
Choi, G., Jesudian, A. B., & Saab, S. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09537-3 · Cited by 1 · see citing works
Romeo, M., Nardo, F. D., Basile, C., Napolitano, C., Vaia, P., Martinelli, G., Gregorio, A. D., Puorto, L. D., Indipendente, M., Dallio, M., et al. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15120597 · Cited by 2 · see citing works
Zeng, Z.-Y., Huang, Z., Wang, Y.-R., Xie, L.-K., Lin, Y., Liang, Y., Liu, Z., Li, D., & Zhang, X. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i20.104891 · Cited by 1 · see citing works
Cristoferi, L., & Invernizzi, P. (2020) · Disease Markers · doi:10.1155/2020/2453908 · Cited by 1 · see citing works
Clinical and serological prognostic markers in primary biliary cholangitis
Wilhelmi, M. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0088
Xu, T., Wang, P., Wang, Z., Wang, L., Li, W., Sun, G., & Liu, M. (2021) · Research Square · doi:10.21203/rs.3.rs-982565/v1
Nagata, T., Takeyama, Y., Shakado, S., Hirai, F., & Nimura, S. (2023) · Cureus · doi:10.7759/cureus.34275
Khakoo, N. S., & Levy, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00039-4
Anti‐GP210 Antibodies as a Primary Driver of Pruritus: A Hypothetical Two‐Hit Model Beyond PBC
Karsulovic, C., Joo, K., & Hojman, L. P. (2025) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.70380
Eruzun, H., & Grønbæk, H. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020915
Константиновна, П. М., Raikhelson, K. L., Павловна, Г. В., Владимировна, П. Е., Marchenko, M. V., & Sokolova, K. S. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-097
Bauer, A., Rawa, T., & Bauer, T. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198461
Reynolds Syndrome: A Rare Autoimmune Overlap Syndrome — A Case Series and Literature ReviewPreprint
Fadili, H., HAMAM, L., Achour, L., Allaoui, A., Smaali, J., Belabbes, F., Ousti, F., Snoussi, M., Zrara, A., Bamou, Y., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-11456007/v1
- Authors
- Huang, C., Han, W., Wang, C., Liu, Y., Chen, Y., & Duan, Z.
- Affiliations
- Capital Medical University (CN)
- Taihe Hospital (CN)
- Corresponding author
- Chen, Yue
- Duan, Zhongping
- Venue
- Disease Markers
- Publisher
- Wiley
- Published
- 2019-10-13
- Volume
- 2019
- Pages
- 1-12
- ISSN
- 0278-0240 (ISSN-L)
- 1875-8630
- PMC
- PMC6815635
- OpenAlex
- W2979645418
- Cited by
- 32
- References
- 28
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 4 · 2023: 5 · 2022: 3 · 2021: 5 · 2020: 3
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Disease Markers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Science and Technology Key Project on “Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Prevention and Treatment” (2017ZX10302201-004-002, 2017ZX10202203-006-001, 2017ZX10201201-002-002, 2017ZX10201201-001-001, 2017ZX10203201-005, 2012ZX10002004-006, ZYLX201711, PX2019062, DFL20151601, ZYLX201806, 2017YFA0103000)
- Beijing Municipal Administration of Hospitals (2017ZX10302201-004-002, 2017ZX10202203-006-001, 2017ZX10201201-002-002, 2017ZX10201201-001-001, 2017ZX10203201-005, 2012ZX10002004-006, ZYLX201711, PX2019062, DFL20151601, ZYLX201806, 2017YFA0103000)
- Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (2017ZX10302201-004-002, 2017ZX10202203-006-001, 2017ZX10201201-002-002, 2017ZX10201201-001-001, 2017ZX10203201-005, 2012ZX10002004-006, ZYLX201711, PX2019062, DFL20151601, ZYLX201806, 2017YFA0103000)
- National Key R&D Program of China (2017ZX10302201-004-002, 2017ZX10202203-006-001, 2017ZX10201201-002-002, 2017ZX10201201-001-001, 2017ZX10203201-005, 2012ZX10002004-006, ZYLX201711, PX2019062, DFL20151601, ZYLX201806, 2017YFA0103000)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- primary biliary cirrhosis, prognosis, disease progression, liver failure, mortality, alkaline phosphatase, IgM, alanine aminotransferase, total bilirubin, prognostic factors, autoimmune liver disease
- MeSH terms
- Aged, Alanine Transaminase, Alkaline Phosphatase, Antibodies, Bilirubin, Female, Humans, Immunoglobulin M, Liver Cirrhosis, Biliary, Male, Middle Aged, Prognosis, Nuclear Pore Complex Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
